Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease

Ophthalmology. 2020 Oct;127(10):1431-1433. doi: 10.1016/j.ophtha.2020.04.009. Epub 2020 Apr 17.

Authors

Jennifer Lee¹, Anjum F Koreishi¹, Katelyn B Zumpf², Caroline L Minkus¹, Debra A Goldstein³

Affiliations

¹ Uveitis Service, Northwestern University, Feinberg School of Medicine, Department of Ophthalmology, Chicago, Illinois.
² Department of Preventative Medicine, Northwestern University, Chicago, Illinois.
³ Uveitis Service, Northwestern University, Feinberg School of Medicine, Department of Ophthalmology, Chicago, Illinois. Electronic address: Debrgold@yahoo.com.

PMID: 32423769
DOI: 10.1016/j.ophtha.2020.04.009

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab / administration & dosage*
Adolescent
Adult
Aged
Anti-Inflammatory Agents / administration & dosage
Child
Child, Preschool
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Treatment Outcome
Uveitis / drug therapy*
Young Adult

Substances

Anti-Inflammatory Agents
Adalimumab